Search Results for "Abnormal Tumor Marker"
Original Source: Tumor markers
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Diff...
Matching Channels
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...
A tumor or tumour is the name for a neoplasm or a solid lesion formed by an abnormal growth of cells (termed neoplastic) which looks like a swelling. Tumor is not synonymous with cancer. A tumor can...
The Asymptomatic Patient With Abnormal Laboratory Test Results
CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. This receptor is expressed by activated, but not by resting, T and B cells. It...
Matching News
The REMARK checklist explained: How to use guidelines on reporting tumor marker prognostic studies
(Public Library of Science) In an "elaboration and explanation" of the Reporting Recommendations for Tumor Marker Prognostic Studies checklist, Doug Altman of the University of Oxford, UK and colleagu...
2013 UK Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 527 pages, 37 tables, and presents a comprehensive analysis of the UK hospital tumor marker testing market, including: Major issues pertaining t...
2013 German Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 530 pages, 40 tables, and presents a comprehensive analysis of the German hospital tumor marker testing market, including: Major issues pertaini...
2013 French Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 533 pages, 43 tables, and presents a comprehensive analysis of the French hospital tumor marker testing market, including: Major issues pertaining...
2013 Japanese Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 537 pages, 42 tables, and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including: Major issues pertaini...
2013 Italian Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 525 pages, 38 tables, and presents a comprehensive analysis of the Italian hospital tumor marker testing market, including: Major issues pertainin...
2013 Spanish Hospital Tumor Marker Testing Market
This new report from Venture Planning Group contains 521 pages, 41 tables, and presents a comprehensive analysis of the Spanish hospital tumor marker testing market, including: Major issues pertai...
Liquid Tumor Marker Control Covers Fifteen Cancer Antigens
A new multianalyte liquid tumor marker control covers a total of 15 commonly tested and esoteric cancer antigens and...
Matching PubMed Articles
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.
BACKGROUND: We evaluated the usefulness of tumor marker doubling time (DT) as an efficacy indicator of a molecular targeted anticancer agent. METHODS: Twenty-five patients with advanced hepatocellular...
The presence of carcinoembryonic antigen (CEA)-containing activated macrophages has been demonstrated in peripheral blood from patients with colorectal carcinoma. Macrophages migrate from the circulat...
Chromogranin A and the Tumor Microenvironment.
Chromogranin A (CgA) is an acidic glycoprotein belonging to a family of regulated secretory proteins stored in the dense core granules of the adrenal medulla and of many other neuroendocrine cells and...
BACKGROUND: The Milan criteria are used to define small hepatocellular carcinoma (HCC) and to select patients for curative treatments. Total tumor volume (TTV) is an alternative parameter for tumor bu...
Objective: The aim of this study was to examine the possible role of Doppler ultrasound assessment of ductus venosus (DV) blood flow at 11(+0)-13(+6) weeks' gestation in fetuses with normal nuchal tra...
